Navigation Links
Soterix Medical Inc., Rogue Resolutions Ltd., and neuroConn GmbH announce MOBILE neuromodulation platform at NYCneuromodulation 2013 conference
Date:12/2/2013

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- At the NYCneuromodulation 2013 conference, Soterix Medical Inc. , Rogue Resolutions Ltd, and neuroConn  GmbH announced the revolutionary MOBILE neuromodulation platform.  The product represents yet another collaboration between Soterix Medical Inc. (based in New York City, NY), Rogue Resolutions Ltd (based in Cardiff, UK), and neuroConn (based in Ilmenau, Germany).  Leveraging over five years of engineering innovations, the MOBILE neuromodulation system is the first non-invasive brain stimulation device designed for high-throughput clinical trials and potential home use.  The MOBILE stimulator is equipped with proprietary tDCS-Limited Total Energy (LTE) technology, which is the only technology optimized for low-energy neuromodulation.    

(Photo: http://photos.prnewswire.com/prnh/20131202/NY25821 )

Each patient receives a customized EASYstrap head-gear with an integrated MOBILE-stimulator. Compliance and safety is achieved through serial distribution of patient MOBILE-kits, each including: 1) A discharge-key that enables the MOBILE-stimulator and is programmed to provide 5 (five) timed sessions of therapy consistent with investigational treatment protocols, 2) Accessory packs including 5 (five) pairs of EASYfit or High-Definition electrodes ensuring consistent therapy thereby removing potential for patient error. Exclusive online MOBILE-smart analysis ensures proper set-up and use.  Discharge-keys are cloud enabled allowing remote physician supervision. 

When compliance and safety cannot be compromised, MOBILE Neuromodulation is the only system with fully integrated electrodes, head-gear, and MOBILE-smart electronics ensuring rigorous and consistent protocols. A system that is sufficiently advanced from any prior device; it could only be developed by the industry leaders in non-invasive neuromodulation. Ideal for extended trials and maintenance phases, the MOBILE device is expected to be deployed into major clinical trials throughout 2014. 

Dr. Abhishek Datta, CTO of Soterix Medical summarizes "In forming this partnership with Rogue Resolutions and neuroConn, an industry leader in neuromodulation engineering, Soterix Medical reaffirms its mission to provide clinical researchers and patients with the most advanced and tested brain stimulation technology.  The MOBILE system was designed to consider every eventuality in large-scale clinical trials and set-up. This is a complete system from patient set-up, to use, to cloud based compliance monitoring. The next generation EASYstrap customized to work with the MOBILE is the most robust and simple head-gear we have designed. Patients receive controlled supplies of electrodes and discharge-keys that are pre-programmed while the MOBILE stimulator includes the most intelligent monitoring systems available to ensure proper set-up. The stimulator itself has just one button.  Tremendous sophistication reduced to unmatched usability. "

BACKGROUND: tDCS- Limited Total Energy (tDCS-LTE) is an exclusive neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, tDCS-LTE is the only tDCS technology platform optimized for robust low-energy Transcranial Direct Current Stimulation. tDCS-LTE is under investigation in susceptible populations including stroke, pediatric, traumatic brain injury, etc. tDCS-LTE is made possible through a proprietary adaptive stimulation limiting the voltage and power required for tDCS. Soterix Medical tDCS-LTE is the only non-invasive neuromodulation technology further optimized for robust deployment in a wide variety of environments including emergency medicine, field-work, home-use, etc.

CAUTION: Investigational device. Federal (or United States) law limits device to investigational use.


'/>"/>
SOURCE Soterix Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Soterix Medical Inc. reports positive results from High-Definition tDCS Fibromyalgia Trial at Harvard Medical School
2. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
3. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
4. Medical Device Developers - Network at BIOMEDevice Boston Next Week
5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
6. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
7. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
8. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Essential Medical Dismisses Patent Case against Masimo and Cercacor
11. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) ... ended December 31, 2015. The Company also filed its Quarterly ... year 2016 with the Securities and Exchange Commission today. ... 31, 2015 --> --> ... increased $2.6 million, or 95%, to $5.4 million from $2.8 ...
(Date:2/11/2016)...  Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... of pets, today announced the submission to FDA of ... Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline ... for the control of pyrexia (fever) in horses were ... --> The Chemistry, Manufacturing, and Controls ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through 6, ... Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. , ... condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its ... on February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This ... to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party ...
(Date:2/11/2016)... , ... February 11, 2016 , ... The book, “Computers ... IT services, what questions to ask your IT consultant before signing a contract and ... your computer network. , “With companies relying heavily on e-mail and technology, it’s more ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
Breaking Medicine News(10 mins):